Strong Support
descriptive
In adults aged 50 and older in India, the recombinant zoster vaccine caused mostly mild or moderate side effects like soreness or fatigue, and no life-threatening reactions, hospitalizations, or autoimmune conditions were linked to the vaccine during six months of monitoring.
73
0
Evidence from Studies
Supporting (1)
73
Community contributions welcome
73
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.
Randomized Controlled Trial
Human
2025 Mar 19Contradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.